학술논문

Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer
Document Type
Article
Source
In: European Journal of Cancer. (European Journal of Cancer, January 2022, 160:100-111)
Subject
Language
English
ISSN
18790852
09598049